COMMUNIQUÉS West-GlobeNewswire

Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/07/2026
CHAPEL HILL, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical [...]
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/07/2026
NAARDEN, The Netherlands and MIAMI, July 02, 2026 (GLOBE NEWSWIRE) -- NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral [...]
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4)
02/07/2026
NEW YORK and WALTHAM, Mass., July 02, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the [...]
Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/07/2026
WILMINGTON, Del., July 02, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), today announced that the Company granted non-qualified stock options to purchase up to an [...]
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/07/2026
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the grant of [...]
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/07/2026
BOSTON, July 02, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that [...]
Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/07/2026
VANCOUVER, British Columbia and BOSTON, MA, July 02, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development [...]
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
02/07/2026
WESTLAKE VILLAGE, Calif., July 02, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, [...]
Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
02/07/2026
IRVINE, California – July 2, 2026 ( GlobeNewswire ) – Mdxhealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced that the Company received a [...]
Results of the Votes of the Combined Shareholders’ General Meeting of June 30, 2026
02/07/2026
Daix (France), New York City (New York, United States), July 2, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused on the development of [...]
Résultats des Votes de l’Assemblée Générale Mixte des Actionnaires Réunie le 30 juin 2026
02/07/2026
Daix (France), New York City (New York, United States), le 2 juillet 2026 – Inventiva (Euronext Paris et Nasdaq : IVA ) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement d’ [...]
Cosmos Health Expands Buyback to 3.42 Million Shares With Additional 770,000-Share Repurchase; Continues Open Market Purchases
02/07/2026
CHICAGO, July 02, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an [...]
CBDrmd.com Launches CBD Gummies and CBD Oil Transparency Initiative
02/07/2026
New educational resource helps adults better understand CBD gummies, CBD oil, product labels, lab reports, ingredient disclosures, THC information, refund policies, and responsible CBD product research. NEW YORK,USA, [...]
GENFIT Announces U.S. Medicare Coverage and Future Reimbursement for NASHnext®, a Non-Invasive Diagnostic Technology to Identify Patients with At-Risk MASH
02/07/2026
Coverage and future reimbursement ( effective August 10, 2026) secured for NASHnext®, Labcorp’s non-invasive blood-based diagnostic test powered by GENFIT’s proprietary NIS4® technology Focuses on patients at highest [...]
GENFIT annonce l’accès à la couverture et le futur remboursement par Medicare aux États-Unis de NASHnext®, une technologie visant à identifier les patients atteints de MASH « à risque »
02/07/2026
Couverture et futur remboursement sécurisés pour NASHnext®, le test diagnostique sanguin non invasif développé par Labcorp, basé sur la technologie propriétaire NIS4® de GENFIT Un ciblage sur les patients les plus à [...]
Declaration voting rights - June 30,2026
02/07/2026
VALNEVA Declaration of shares and voting rights Status as of June 30, 2026 __________________________________________________________________________________________ Company name: VALNEVA Registered office: Îlot Saint- [...]
Déclaration droits de vote - 30 juin 2026
02/07/2026
VALNEVA Déclaration d’actions et de droits de vote Statut au 30 juin 2026 __________________________________________________________________________________________ Dénomination sociale : VALNEVA Adresse du siège social [...]
Profusa Announces 1-for-25 Reverse Stock Split
02/07/2026
BERKELEY, California, July 02, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology platform enabling the [...]
SRX Global Makes Strategic Investment in Critical and Precious Minerals Development Company, Greenland Mines
02/07/2026
NORTH PALM BEACH, Fla., July 02, 2026 (GLOBE NEWSWIRE) -- SRX Global, Inc. (NYSE American: SRXH) (the "Company", or “SRX”), an AI-enabled platform dedicated to generating returns across high-conviction operating [...]

Pages